

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

PROTOCOL CODE: GIGAVCOXT

Page 1 of 2

DOCTOR'S O	RDERS	Ht	cm	Wt	kg	BSA	m²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form							
DATE:	To be given: Cycle #:						
Date of Previous Cycle:							
□ Delay treatment week(s) □ CBC & diff, platelets, creatinine day of treatment  May proceed with doses as written if within 96 hours ANC greater than or equal to 1.2 x 10 <sup>9</sup> /L, Platelets greater than or equal to 75 x 10 <sup>9</sup> /L, and Creatinine Clearance greater than or equal to 50 mL/minute  Dose modification for: □ Hematology □ Other Toxicity  Proceed with treatment based on blood work from							
PREMEDICATIONS: Pa							
ondansetron 8 mg prior to chemotherapy dexamethasone 8 mg or 12 mg (circle one) prior to chemotherapy NO ice chips  Other:							
CHEMOTHERAPY: ☐ Repeat in three weeks oxaliplatin line to be primed with D5W; trastuzumab line to be primed with NS							
oxaliplatin 130 mg/m² x BSA = mg  □ Dose Modification: mg/m² x BSA = mg  IV in 250 to 500 mL D5W over 2 hours  To reduce incidence of vascular pain: □ 250 mL total volume of D5W to be administered concurrently with oxaliplatin at a maximum rate of 125 mL/h □ 500 mL total volume of D5W to be administered concurrently with oxaliplatin at a maximum rate of 250 mL/h							
☐ Cycle 1 Only:  trastuzumab 8 mg/kg x kg = mg IV in 250 mL NS over 1 hour 30 minutes.  Observe for 1 hour post infusion**							
•	Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190						
Drug Brand (F	Pharmacist to complete.	Please print.)	Р	Pharmacist Initial and Date			
trastuzumab							
Cycle 2  trastuzumab 6 mg/kg x kg =mg IV in 250 mL NS over 1 hour every three weeks xCycle(s) Observe for 30 minutes post infusion**  Pharmacy to select trastuzumab brand as per Provincial Systemic Therapy Policy III-190  Drug Brand (Pharmacist to complete. Please print.) Pharmacist Initial and Date  trastuzumab							
	=-				laia	NATURE	
DOCTOR'S SIGNATURI	<b>=:</b>				UC	NATURE:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="https://www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: GIGAVCOXT

Page 2 of 2

DATE:	To be given:	Cycle #:					
CHEMOTHERA	PY: Repeat in three weeks						
Observe for 30 **Observation peri	ubsequent: 6 mg/kg x kg =mg IV in 250 mL NS over 0 minutes post infusion**. od not required after 3 treatments with no reaction rastuzumab brand as per Provincial Systemic Therapy Polic Brand (Pharmacist to complete. Please print.)		Cycle(s)				
trastuzumab							
acetaminophen 325 to 650 mg PO PRN for headache and rigors							
capecitabine 1000 mg/m² or x BSA x (%) =mg PO BID x 14 days (refer to Capecitabine Suggested Tablet Combination Table for dose rounding)							
RETURN APPOINTMENT ORDERS							
<ul> <li>□ Return in three weeks for Doctor and Cycle</li> <li>□ Return in six weeks for Doctor and Cycle &amp; Book chemo x 2 cycles</li> <li>□ Last Cycle. Return in three weeks for GIGAVTR (to continue single agent trastuzumab)</li> </ul>							
CBC & Diff, Platelets, Creatinine, Bilirubin, ALT, Alk Phos, Sodium, Potassium, Magnesium, Calcium prior to each cycle							
☐ INR weekly ☐ ECG ☐ Other tests: ☐ ☐ Radiologic ev ☐ Weekly Nursi ☐ Consults: ☐ See general of	☐ INR prior to each cycle ☐ CEA ☐ CA 19-9 ☐ MUGA scan or ☐ Echocardiogram raluation right Assessment for (specify concern):						
DOCTOR'S SIG	NATURE:	SIGNATUR	E:				
		UC:					